Liquidia (LQDA) just reported second quarter 2026 results that shifted the company from loss to profit, with higher revenue, positive net income, and earnings per share that moved into positive territory.

The earnings release has come after a sharp pullback, with Liquidia’s share price down 10.52% over the last day and 11.59% over the past week. However, the 1-year total shareholder return of 212.66% and very large 5-year total shareholder return indicate that long-term momentum has been powerful.

If strong performance in Liquidia has you thinking about other potential opportunities in healthcare, this could be a good moment to review 43 healthcare AI stocks.

After a sharp pullback and a share price well below both analyst targets and intrinsic estimates, Liquidia now sits in a wide gap between market price and implied fair value. Is that gap a warning sign or an opportunity?

Most Popular Narrative: 39.4% Undervalued

Liquidia's most widely followed narrative pegs fair value at $130.00 compared with the recent close at $78.79. This presents a wide valuation gap that hinges on execution and litigation outcomes.

Early profitability and positive adjusted EBITDA in the first full launch quarter, together with disciplined R&D and SG&A spending, are creating operating leverage that can support faster growth in operating income and net margins as sales scale.

Read the complete narrative. Read the complete narrative.

Want to see why some analysts think Liquidia could support that higher price tag? The narrative focuses on rapid top line expansion, widening margins and a future earnings profile that assumes the treprostinil franchise matures far beyond today's financials.

Result: Fair Value of $130.00 (UNDERVALUED)

However, the bullish Liquidia story still hinges on unresolved patent disputes and the company’s reliance on YUTREPIA, which could quickly change sentiment if outcomes disappoint.

Another View on Liquidia’s Valuation

The earlier narrative casts Liquidia as deeply undervalued, yet the current P/S ratio of 27.2x tells a different story. That compares with about 5x for the broader US Pharmaceuticals industry, 13.1x for peers, and a fair ratio of 13.5x that the market could drift toward over time.

If sentiment cools, a move closer to that fair ratio would mean a much lower implied value, even if the bullish growth case plays out. On the other hand, sustained optimism could keep the premium intact for longer. Consider which side of that trade off feels more realistic to you right now.

Next Steps

With such a mixed setup around Liquidia, you may want to review the numbers and sentiment yourself and move quickly to form an independent stance using 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Liquidia?

If Liquidia has your attention today, do not stop there. Use this moment to scan a wider set of stocks and refresh your watchlist with fresh ideas.

• Spot potential bargains early by reviewing companies that screen as attractively priced on fundamentals through the 49 high quality undervalued stocks.
• Steady your portfolio with candidates that show financial resilience using the 86 resilient stocks with low risk scores.
• Hunt for overlooked opportunities with strong underlying metrics by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.